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Abstract
Background: Irritable Bowel Syndrome (IBS) is highly prevalent and is associated with a substantial economic
burden. Cognitive behavior therapy (CBT) has been shown to be effective in treating IBS. The aim of this study was
to evaluate the cost-effectiveness of a new treatment alternative, internet-delivered CBT based on exposure and
mindfulness exercises.
Methods: Participants (N = 85) with IBS were recruited through self-referral and were assessed via a telephone
interview and self-report measures on the internet. Participants were randomized to internet-delivered CBT or to a
discussion forum. Economic data was assessed at pre-, post- and at 3-month and 1 year follow-up.
Results: Significant cost reductions were found for the treatment group at $16,806 per successfully treated case.
The cost reductions were mainly driven by reduced work loss in the treatment group. Results were sustained at
3-month and 1 year follow-up.
Conclusions: Internet-delivered CBT appears to generate health gains in IBS treatment and is associated with cost-
savings from a societal perspective.
Keywords: Cognitive behavior therapy internet, IBS, cost-effectiveness analysis
Background
Irritable bowel syndrome (IBS) is a highly prevalent gas-
trointestinal disorder [1] that is associated with produc-
tion losses [2,3] and increased levels of health service
utilization [3,4]. The high prevalence rate combined with
the costs associated for each afflicted individual makes
IBS a considerable economic burden for society. Research
indicates that psychological interventions - such as cogni-
tive behavior therapy (CBT), hypnotherapy and psycho-
dynamic therapy - can be effective in reducing IBS
symptoms [5]. In addition, there is some evidence indi-
cating that psychological treatments are cost-effective.
In a study by Creed et al. [6], 171 patients with IBS were
randomized to receive either 8 sessions of individual
psychodynamic therapy, paroxetine, or care as usual.
At one-year follow-up, the psychotherapy condition was
associated with significant reductions in health care con-
sumption when compared to care as usual, whereas the
paroxetine group did not show a similar reduction. In a
study by McCrone et al. [7], CBT was found to have a
reasonable short-term cost-effectiveness but not beyond
3-month follow-up. In summary, although psychological
treatments are effective in reducing IBS symptoms there
is insufficient evidence of their cost-effectiveness.
Our research group has recently conducted a rando-
mized controlled trial of internet-delivered CBT for IBS
[8]. The main reason for using the internet as method of
d e l i v e r yi st oi n c r e a s et h ea v a ilability of the treatment.
Evidence-based psychological treatments are often una-
vailable due to a lack of properly trained therapists [9].
Internet-delivered CBT with minimal therapist contact
has been found to be effective for a number of psychiatric
and somatic problems [10,11], and are likely to be cost-
effective and more accessible to patients [12]. However,
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internet-delivered CBT.
Methods
Sample
Participants were eligible for the study if they had been
diagnosed with IBS by a physician before applying for
the study and if they presently fulfilled the Rome III cri-
teria for IBS [13]. The Montgomery Åsberg Depression
Rating Scale - Self report [MADRS-S; [14]] was used to
exclude participants, fulfilling criteria for suicide idea-
tion (item 9 ≥ 4), and severe depressive symptoms(total
score ≥ 30). Participants fulfilling criteria for substance
dependence according to Alcohol Use Disorders Identi-
fication Test [AUDIT; [15]] or Drug Use Disorders
Identification Test [DUDIT; [16]] and participants suf-
fering from psychosis, manic episode, or anorexia were
also excluded.
Procedure
Figure 1 displays participant flow through the selection
procedure, randomization and assessments. The partici-
pants were recruited through self-referral from the gen-
eral adult population in Sweden. A total of 193
individuals applied for the study, 98 were interviewed
and 86 were included for randomization. Telephone
interviews were conducted by graduate psychology stu-
dents or psychologists and included structured questions
a b o u tR o m eI I I - c r i t e r i aa n da l s ot h eM i n i - I n t e r n a t i o n a l
Neuropsychiatric Interview [MINI; [17]] to assess any
psychiatric co-morbidity that could be cause for exclu-
sion. All interviews were reviewed by the study’sg a s t r o -
enterologist who made the final decision if a participant
should be included in the study. After having been ran-
domized to the treatment condition one participant
underwent a colostomy and was subsequently excluded
from the study and all further data analysis. Demo-
graphics for the study participants are displayed in
Table 1.
The study included pre- and post-treatment assess-
ments for the treatment condition. Follow-up data were
collected at 3-month follow-up for the treatment condi-
tion. After ten weeks, the participants in the control
condition were crossed over to the active treatment. Fol-
low-up data were also collected for all participants in
the study approximately one year (15 to 18 months)
after receiving the treatment.
The study protocol was approved by the regional
ethics committee in Stockholm, Sweden.
Interventions
The experimental group was given a ten-week internet-
delivered cognitive behavioral treatment with therapist
support via e-mail. The mean therapist time spent on
each participant was 165 minutes (SD = 85 min). The
treatment consisted of graded exposure to IBS-symptoms
and mindfulness exercises. The treatment protocol is
further described in Ljótsson et al. [18] and Ljótsson et
al. [8]. Participants in the control group took part in a
discussion forum and could contact a therapist for gen-
eral support if they wished (mean therapist time was
10 minutes, SD = 23).
Clinical outcome
The primary outcome was the Gastrointestinal Symptom
rating scale-IBS version (GSRS-IBS) [19]. A clinically
significant improvement was defined as a 50% reduction
of GSRS-IBS score [20].
Cost assessment
Cost data were obtained with the Trimbos and Institute
of Medical Technology Assessment Cost Questionnaire
for Psychiatry (TIC-P) [21]. In this questionnaire, partici-
pants report their health care consumption during the
last month (e.g. GP visits), as well as time spent in infor-
mal health enhancing activities (e.g. self-help groups and
informal care from friends). Participants also report their
level of sick leave and reduced work capacity both at
work and in the domestic realm and unemployment
status during the last month.
T h e s es e l f - r e p o r t sw e r eu s e dt oe s t i m a t et h ec o s t so f
each participant’s health care consumption, work loss,
and work cutback. Medication costs were based on the
free market price in Sweden. Costs from health service
visits were estimated using established tariffs in Sweden.
The human capital approach was used for valuation of
the productivity losses, which means that monetary losses
associated with work loss and work cutback were based
on the participants’ gross earning for the full length of
their sick leave [22]. Gross earnings were estimated using
the average salary in Sweden by education level. Domes-
tic losses were estimated at $ 13.17 per hour, reflecting
t h ef r e em a r k e tp r i c eo fd o m e s t i ch e l p[ 2 3 ] .T h ec o s t s
were originally computed in Swedish Crowns and then
converted into US $ using the purchasing power parities
of the OECD for the reference year 2008 [24].
The direct medical costs associated with the interven-
tion were mainly driven by the costs of therapists. In this
study, the therapists were graduate psychology students
under supervision, but in the analysis we used the full
economic cost price of a licensed clinical psychologist.
The time the therapist spent on treating the partici-
pants was registered and multiplied by this cost. We also
estimated the costs of the participants’ time, again at
$13.17/hour, thus equating it with domestic help and
assuming that people engaged in the intervention after
office hours. The cost estimations of the control group
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Page 2 of 7were based on the time spent on the internet discussion
forum. The cost estimations in the treatment group were
based on the self-reported time the participants spent
reading the treatment material and performing home-
work exercises plus the time spent on the discussion
forum,
Analysis
The analysis was conducted in accordance with the
intention to treat principle, which means that all partici-
pants were included in analysis regardless of adherence
to treatment. Missing data were imputed using the last
observation carried forward method. The statistical
 
 
 
Applied for the study 
(n=193) 
Excluded (n=84) 
Did not complete screening or did 
not submit written consent 
Completed screening and 
submitted written consent 
(N=109) 
Excluded (n=6) 
Symptom debut after 50:2 
Symptom since less than 2 yrs: 1 
MADRS-S>30:1 
Not diagnoses by md: 1 
Other GI disease:  1 
Included for interview 
(n=103) 
Interviewed (n=98) 
Included and randomized 
(N=86) 
Treatment condition 
(n=43) 
Internet chat forum 
(n=43) 
Participated in post 
assessment (n=38) 
Participated in post 
assessment (n=43) 
 
Participated in 3 
month follow-up 
(n=38) 
Participated in 12 
month follow-up 
(n=39) 
Participated in 12 
month follow-up 
(n=37) 
Recieved CBT 
 
Excluded (n=5) 
Unreachable: 3 
Declined to participate: 2 
Excluded (n=12) 
Other GI disease: 2 
Alarm symptoms present: 1 
Suicide ideation: 1 
Did not meet Rome III-criteria: 6 
Declined: 2 
Excluded after 
randomization (n=1) 
 
Figure 1 Flowchart of study participants. (no figure legend).
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Page 3 of 7analysis was conducted in four steps using STATA
IC/11.0 (Stata Corp).
First, the cost differences between the treatment and
control groups were estimated at pre-treatment and
post-treatment. All costs were extrapolated to a
12-month period. Since the cost data were assumed to
be non-normally distributed, p-values were estimated
using a general linear model while employing non-
parametric bootstrap analysis (5,000 replications). Such
analyses are considered to generate robust estimates of
standard errors of the costs [25].
Secondly, we compared the counts of clinically signifi-
cant improvements across the conditions. Using a Pois-
son regression framework allowed us to test if the rate
of favorable treatment responses in the experimental
condition was higher than 1 relative to the control con-
dition. The number needed treat (NNT) was computed
as the inverse of the risk difference, which was obtained
under a linear probability model [26].
Thirdly, the incremental cost-effectiveness ratio (ICER)
was estimated. We computed pre-post differences in
costs and effects. We then computed differences in costs
and effects between both conditions taking the cost dif-
ference over the effect difference: (C(exp) - C(ctr))/(E
(exp) - E(ctr)). C is the difference of the costs of IBS and
the intervention between the pre and post assessments. E
refers to the treatment response between both conditions
[22]. This calculation was repeated 5,000 times (for each
bootstrap sample) generating a scatter of simulated
ICERs across the ICER plane (see Figure 2).
Fourthly, the robustness of the results was tested in
four different sensitivity analyses. First, the main analysis
was repeated with only the direct medical costs
included, hence narrowing the economic evaluation to a
health service perspective. Second, the total costs were
calculated with the unemployment costs excluded. This
was done because the costs due to productivity losses
from unemployment are large when accumulated over a
12-month period and could (in spite of randomization)
be affected by factors not associated with IBS. Third, the
missing data were reanalyzed using linear regression
imputation as implementedi nS T A T A .T h i sw a sd o n e
to test whether last observation carried forward was
indeed a more conservative imputation method. Fourth,
we investigated the long-term impact on the ICER using
3-month and 1-year follow-up economic data. Since the
control group was crossed over to treatment there was
no comparison group at the follow-up assessment. The
3-month and 1 year follow-up of the treatment group
data were therefore compared with the post-treatment
data of the control group, thus assuming that the con-
trol group would have been unchanged if had been
untreated during the follow-up periods. This was done
to test whether the extrapolation to a 12-month period
was a reliable analysis procedure.
Lastly, since the control group was crossed over to
treatment and also participated in the follow-up, the
long-term costs were calculated separately for that group.
Results
Costs
Table 2 presents the annual per capita costs of IBS at
pre-treatment and post-treatment assessment for both
treatment and control groups and 3-month and 1 year
follow-up for the treatment group. At post treatment,
we found significant cost differences regarding the gross
total monetary change, Z = -2.06, P <0 . 0 5 ,a sw e l la s
the indirect non-medical costs, Z = -2.20, P < 0.05.
Treatment efficacy
The fraction of recovered participants in the interven-
tion condition at post treatment was 15/42 = 0.36 and
1/43 = 0.02 in the control condition. Hence, the likeli-
hood ratio for a favorable treatment response was 0.36/
0.02 = 15.36, representing a 15-fold increase of the
recovery rate in the intervention relative to the control
condition (95% confidence interval 2.1 to 111.1). This
Table 1 Demographics
Total
(n = 85)
CBT
(n = 42)
Control
(n = 43)
Sex
Male (n) 13 7 6
Female (n) 72 35 37
Age
mean years (sd) 34.6 (9.4) 36.4 (10.1) 32.8 (8.6)
min-max years 20-61 21-61 20-50
Years since diagnosis
mean years (sd) 6.3 (7.3) 7.2 5.5
min-max years 0-41 0-41 0-22
Figure 2 Cost-effectiveness plane. (no figure legend).
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Page 4 of 7was statistically significant, Z= 2.64, P < 0.01. The NNT
to generate one clinically significant improvement was
2.99 (95%CI 2 to 5), which means that three patients
need to receive the intervention to generate one clini-
cally significant improvement. At the 3-month follow-
up, the fraction of recovered participants in the CBT
condition was 14/42 = 0.33, and at one-year follow-up
this figure was 18/42 = 0.43. In sum, the effects appear
to be sustained over a 12-month period.
Cost effectiveness
T h ec o s tc h a n g ef o rt h et r e a t m e n tg r o u pw a s1 6 , 9 8 8-
20,867 = -3879. The cost change in the control group was
16,872 - 15,036 = 1835. The incremental cost effectiveness
ratio (ICER) was (-3879 - 1835)/(0.36 - 0.02) = -16,806.
This means that each significant clinical improvement in
IBS is associated with a societal cost-reduction of $16,806.
Figure 2 presents the scatter of simulated ICERs across
the four quadrants of the ICER plane. If the bulk of simu-
lated ICERs appear in the southeast quadrant of the figure,
lower costs are associated with a health gain. From a cost-
effectiveness perspective, this is the most favorable out-
come. If a majority of the simulated ICERs appear in the
northwest quadrant, higher costs are associated with a
lowered effectiveness, thus making the new intervention
unacceptable from a cost-effectiveness perspective. Nearly
all simulated ICERs (96%) were located in the southeast
quadrant, indicating that the treatment produced benefi-
cial effects and reduces costs for society compared to a no
treatment control condition.
Sensitivity analyses
When only including direct medical costs in the estima-
tion, 48% of the simulated ICERs were located in the
southeast quadrant. When analyzing all data but exclud-
ing the unemployment variable, 41% of the dots were
located in the southeast quadrant. Data were reanalyzed
using regression imputation of missing data instead of
last observation carried forward (4 imputations, R-
square = 0.93). A majority (98%) of the simulated ICERs
were still located in the southeast quadrant, attesting to
the robustness of our findings. Finally in order to inves-
tigate the long-term impact, we repeated the analyses
with follow-up economic data for the treatment group.
Using 3-month and 1-year follow-up data, 97% and 89%
of the dots were located in the southeast quadrant,
respectively.
The control group at follow up
After the post-treatment the control group was crossed
over to treatment. At the 1 year follow-up the group
also presented with cost reductions (pre treatment;
$15,036, follow-up; $13,008). Additionally 19/43 of the
control group participants reported clinically significant
symptom relief.
Discussion
The aim of this study was to determine whether internet-
delivered CBT would be a cost-effective or perhaps even
a cost-saving intervention for IBS. The results give preli-
minary evidence of the internet-delivered treatment as a
cost-effective way of offering treatment; better still, our
observations suggest that the intervention is cost saving
from a societal point of view. Participants in the treat-
ment condition demonstrated significant reductions in
IBS symptoms compared to the control condition. These
improvements were accompanied by cost reductions at
post-treatment and at follow-up. While the intervention
Table 2 Mean annual costs
Annual per capita cost ($)
Pre treatment Post treatment 3-month
follow-up
12-month
follow-up
CBT(SE) Control(SE) CBT(SE) Control(SE) CBT(SE) CBT(SE)
Direct medical costs 3,580
(757)
3,241
(706)
3,222
(756)
3,547
(790)
2,096
(445)
1,754
(450)
Health care visits 3,444 (756) 3,053 (670) 3,153 (760) 3,323 (746) 1,895 (435) 1,666 (443)
Medications 136 (19) 188 (70) 69 (18) 225 (73) 38 (8) 88 (26)
Direct non-medical costs 1,045 (370) 1,086 (498) 958 (449) 571 (305) 735 (330) 371 (131)
Indirect non-medical costs 16,241 (2893) 10,709 (2308) 11,227 (2544) 12,619 (2482) 11,324 (2478) 13,677 (2906)
Workloss 11,934 (1668) 6,167 (1295) 10,086 (2567) 9,674 (2505) 9,561 (2511) 12,314 (2951)
Work cutback 2,919 (864) 3,545 (943) 1,097 (292) 2,945 (734) 1,262 (323) 1,362 (402)
Domestic 1,388 (301) 997 (181) 921 (225) 1102 (300) 500 (117) 529 (168)
Total (excl. intervention
costs)
20,867 (3395) 15,036 (2615) 15,407 (3048) 16,737 (2713) 14,156 (2660) 15,802 (3023)
Intervention costs 1,580 (158) 135 (26) 1,580 (158) 1,580 (158)
Total (incl. intervention
costs)
20,867 (3395) 15,036 (2615) 16,988 (3068) 16,872 (2720) 15,736 (2645) 17,382 (3038)
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Page 5 of 7did introduce some costs of its own, these costs were off-
set by greater productivity levels both at paid work and
in the domestic realm. Thirty-six percent of the partici-
pants in the treatment condition were clinically improved
and for each case of clinical improvement in IBS symp-
toms $16,806 of societal costs were saved. Irrespective of
modeled scenario and choice of imputation method the
online CBT intervention was associated with cost offsets,
demonstrating robustness of our findings. The control
g r o u ps h o w e ds i m i l a ri m p r o v ements and cost-savings
after being crossed over to treatment.
The results from this trial differ from the McCrone
et al. [7] and Creed et al. [6] studies. In the Creed et al.
study, significant reductions in health care costs were
found at the one-year follow-up but no significant
reductions in work loss for the psychotherapy group.
One possible explanation for this difference could be
that this study used a broader perspective including
both work cutback as well as domestic loss in the cost-
effectiveness analysis. In the McCrone et al. study, the
CBT group did not show any significant reductions in
work loss and the treatment was not cost-effective
beyond 3-month follow-up. In the original treatment
s t u d yt h a tt h eM c C r o n ee ta l .r e p o r tw a sb a s e do n ,t h e
participants’ improvements in symptom actually
declined after the 3-month follow-up [27]. In contrast,
the participants in our study demonstrated long-term
maintenance of symptom reduction that could explain
the long-term cost effectiveness. By and large, the
results from this study provide additional evidence for
internet-delivered CBT as a cost-effective treatment
alternative for IBS.
Our study has several limitations. First, the cost data
was collected using self-reports and the accuracy of this
methodology can be open-to-question. However, the
recall period was relatively short (4 weeks) and there is
no reason to assume that inaccuracies overly bias any of
the two treatment conditions. In addition, previous
research studies have indicated that self-reports are as
reliable as administratively recorded data [28]. The TIC-
P has been used in numerous studies [29-31] and has
the advantage of being a broad measure covering health
care uptake and productivity losses both in paid work as
well as in the domestic realm. Therefore, the self-report
methodology could be regarded as a feasible choice of
measurement. Secondly, the use of 50% decline in IBS
symptoms measured as criterion for clinically significant
improvement might be inappropriate. This criterion has
been used in several trials [20] of psychological treat-
ment but other measures of clinically significant
improvement have been proposed. The participants’
subjective experience of “adequate relief” [32] has been
used in both pharmacological [33] and psychological
trials [9]. A 50 point reduction in score on the IBS-SSS
[34] has also been used as clinically significant improve-
ment in symptoms. These differences in determining a
clinically significant outcome are problematic as they
make it difficult to compare trials and treatments. It
would therefore have been preferable if at least one of
the adequate relief and IBS-SSS measures had been
included in this study. Thirdly, the control condition
participants were randomized to a waiting list and were
therefore aware that they would eventually receive the
treatment. This factor could possibly have an impact on
the cost-effectiveness results since the study design did
not allow control for attention and expectancy of
improvement. A proper attention control condition
would have provided a more reliable estimate the cost-
effectiveness of the specific treatment used. Fourthly,
the calculations are based on internet CBT in a research
setting and the real market price of such interventions
is still unknown. Fifth, we did not directly ask the parti-
cipants about their gross earning but instead used the
average Swedish salary based on the participant’s educa-
tion level. This lack of information could possible pro-
duce errors in the mean cost calculations regarding
production losses. However, the participants were ran-
domized and potential errors should not affect the
between group ICER estimations. Finally, as the control
group was crossed over to treatment no comparison
group was available at the 3-month and 1 year follow-
up. The short experimental time period makes the
extrapolated estimates of long-term cost-effectiveness
somewhat less reliable. However, when repeating the
analyses with 3-month and 1 year follow-up clinical
data, the scatter of the simulated ICERs over the cost-
effectiveness plane did not differ in any substantial way
and would not change our conclusions.
Conclusions
To summarize, the findings from this study indicate that
internet-delivered CBT for IBS can both be effective in
treating IBS and generate cost savings for the society.
Future evaluations should continue to investigate the
cost-effectiveness as well as look more closely at the
economic ramifications with regard to favorable treat-
ment response. More research is also needed to expand
our knowledge concerning the economic impact of
internet-delivered CBT for IBS. We recommend that
future studies use a more potent placebo condition and
longer follow-up periods.
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